^
Association details:
| Biomarker: | ALK fusion + EGFR exon 19 deletion + BRAF G466V + MAP2K1 F129L |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | ALK inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
NGS-based liquid-biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step towards personalized NSCLC treatment
Published date:
05/31/2021
Excerpt:
We collected 26 plasma and two cerebrospinal fluid samples from 24 advanced ALK-positive NSCLC patients at disease progression to an ALK-I...Specifically, a deletion in exon 19 in EGFR, a non-V600 BRAF mutation (G466V) and the F129L mutation in MAP2K1 were identified in four patients who showed no objective survival benefit from ALK-Is.
DOI:
https://doi.org/10.1002/1878-0261.13033
